Valneva, LimmaTech Get FDA Fast Track Designation for Shigellosis Vaccine Candidate

MT Newswires Live10-17

Valneva (VALN) and LimmaTech Biologics got a fast track designation from the US Food and Drug Administration for their tetravalent bioconjugate shigellosis vaccine candidate.

The expected regulatory pathway for Shigella4V involves a combination of controlled human infection model studies to support potential initial approval in adults, followed by field efficacy studies for the possible expansion to children, the companies said Wednesday in a statement.

In August, Valneva entered into a partnership and exclusive licensing agreement with LimmaTech2 for the development, manufacturing and commercialization of Shigella4V.

Shares of Valneva jumped 6.4% in recent trading Wednesday.

Price: 5.84, Change: +0.35, Percent Change: +6.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476944262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-17 00:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476944262","market":"sg","top_or_hot":-1,"title":"Valneva, LimmaTech Get FDA Fast Track Designation for Shigellosis Vaccine Candidate","media":"MT Newswires Live","content":"<html><body><p> Valneva (VALN) and LimmaTech Biologics got a fast track designation from the US Food and Drug Administration for their tetravalent bioconjugate shigellosis vaccine candidate.</p><p>The expected regulatory pathway for Shigella4V involves a combination of controlled human infection model studies to support potential initial approval in adults, followed by field efficacy studies for the possible expansion to children, the companies said Wednesday in a statement.</p><p>In August, Valneva entered into a partnership and exclusive licensing agreement with LimmaTech2 for the development, manufacturing and commercialization of Shigella4V.</p><p>Shares of Valneva jumped 6.4% in recent trading Wednesday.</p><p>Price: 5.84, Change: +0.35, Percent Change: +6.37</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva, LimmaTech Get FDA Fast Track Designation for Shigellosis Vaccine Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva, LimmaTech Get FDA Fast Track Designation for Shigellosis Vaccine Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 00:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valneva (VALN) and LimmaTech Biologics got a fast track designation from the US Food and Drug Administration for their tetravalent bioconjugate shigellosis vaccine candidate.The expected regulatory ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4567","symbol_name":"ESG概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476944262","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476944262","pubTimestamp":1729095954,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Valneva  and LimmaTech Biologics got a fast track designation from the US Food and Drug Administration for their tetravalent bioconjugate shigellosis vaccine candidate.The expected regulatory pathway for Shigella4V involves a combination of controlled human infection model studies to support potential initial approval in adults, followed by field efficacy studies for the possible expansion to children, the companies said Wednesday in a statement.In August, Valneva entered into a partnership and exclusive licensing agreement with LimmaTech2 for the development, manufacturing and commercialization of Shigella4V.Shares of Valneva jumped 6.4% in recent trading Wednesday.Price: 5.84, Change: +0.35, Percent Change: +6.37","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4567":"ESG概念","BK4104":"贸易公司与经销商","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4539":"次新股","FAST":"快扣","VALN":"Valneva SE"},"translate_title":"Valneva和LimmaTech获得FDA志贺氏菌病候选疫苗快速通道指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FAST":1,"VALN":0.9},"content_text":"Valneva (VALN) and LimmaTech Biologics got a fast track designation from the US Food and Drug Administration for their tetravalent bioconjugate shigellosis vaccine candidate.The expected regulatory pathway for Shigella4V involves a combination of controlled human infection model studies to support potential initial approval in adults, followed by field efficacy studies for the possible expansion to children, the companies said Wednesday in a statement.In August, Valneva entered into a partnership and exclusive licensing agreement with LimmaTech2 for the development, manufacturing and commercialization of Shigella4V.Shares of Valneva jumped 6.4% in recent trading Wednesday.Price: 5.84, Change: +0.35, Percent Change: +6.37","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476944262"}